Astellas Presents Cancer Treatment Advances at ESMO 2026

Astellas Pharma Inc. presented several research findings related to the treatment of hard-to-treat cancers at the ESMO 2026 congress (European Society for Medical Oncology). The company's focus is on advancing patient care and innovation.

Data on the combination therapy of PADCEV™ (enfortumab vedotin) and pembrolizumab were presented. The results demonstrated a durable survival benefit in advanced bladder cancer. This combination therapy offers new avenues for patients with previously challenging disease.

Additionally, research findings for VYLOY™ (zolbetuximab) were shared. These studies reinforce the significance of the CLDN18.2 molecule in shaping treatment decisions for gastric cancer. Understanding CLDN18.2's role may lead to more targeted therapies and improved patient outcomes.

The presented findings highlight Astellas' commitment to cancer research and the development of novel therapeutic approaches. The company aims to address unmet medical needs for patients and healthcare providers in oncology.